<DOC>
	<DOCNO>NCT02310867</DOCNO>
	<brief_summary>The purpose study determine safety efficacy hand transplantation treatment patient loss limb elbow , The study focus patient loss limb . The primary endpoint ability use tranplanted limb activity daily live 18 month follow transplantation measure quantitative functional test . Study activity include several study visit 18 month include ; demographic , medical history , vital sign , psychosocial evaluation , urine , blood test , chest x-ray , bone density scan , biopsy . Subjects 18-65 willing travel site loss limb include study evaluation . Risks study include risk rejection infection transplant . Additional risk associate procedure include blood draw , biopsy , x-ray , potential loss confidentiality . All patient data keep electronically accordance requirement Duke University . In addition experimental data , database include recipient donor demographic transplant relevant medical history , range motion , sensation , immunosuppressive medication . Data record report accordance standard require United Network Organ Sharing ( UNOS ) .</brief_summary>
	<brief_title>Immunomodulation Optimize Vascularized Composite Allograft Integration Limb Loss Therapy</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Patients 1865 year old loss limb 2 . Willingness legal ability give inform consent 3 . Willingness travel study site protocol specific sample take , case , ability send sample via overnight mail Any condition preclude serial followup Any condition would likely increase risk protocol participation confound interpretation data Any active malignancy history malignancy lymphoma Inability unwillingness comply protocol monitoring therapy immunodeficiency syndrome ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>hand transplantation , amputation</keyword>
</DOC>